Origen Therapeutics, Inc. Appoints Phil Leighton as Director of Research and Announces Departure of Robert Etches, VP of Research

EMERYVILLE, Calif.--(BUSINESS WIRE)--Origen Therapeutics today announced a change in the research management of the company appointing Dr. Phil Leighton as Director of Research, following the departure of Robert Etches, Ph.D., D. Sc., Vice President of Research. This change marks the company’s transition from development of its proprietary avian transgenic technology to the application of that technology to product development in the pharmaceutical, food and agricultural arenas.